#Rilzabrutinib Phase 3 LUNA 3 results in #thrombocytopenia at #ASH24
16/18 patients responded in two weeks 🧪
16/18 patients responded in two weeks 🧪
December 8, 2024 at 11:54 PM
#Rilzabrutinib Phase 3 LUNA 3 results in #thrombocytopenia at #ASH24
16/18 patients responded in two weeks 🧪
16/18 patients responded in two weeks 🧪
Rilzabrutinib Nets Approval in Pretreated Immune Thrombocytopenia #oncology #thrombocytopenia
www.onclive.com/view/rilzabr...
www.onclive.com/view/rilzabr...
Rilzabrutinib Nets Approval in Pretreated Immune Thrombocytopenia
Rilzabrutinib has been approved by the FDA for persistent or chronic immune thrombocytopenia after an insufficient response to prior therapy.
www.onclive.com
September 2, 2025 at 6:44 PM
Rilzabrutinib Nets Approval in Pretreated Immune Thrombocytopenia #oncology #thrombocytopenia
www.onclive.com/view/rilzabr...
www.onclive.com/view/rilzabr...
Study: Rilzabrutinib, a BTK inhibitor, shows promise in Phase 2 trial for antihistamine-refractory chronic spontaneous urticaria. PMID:40266575, JAMA Dermatol 2025 https://doi.org/10.1001/jamadermatol.2025.0733 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
https://doi.org/10.1001/jamadermatol.2025.0733
No description available
doi.org
May 14, 2025 at 3:10 AM
Rilzabrutinib acts through multi-immune modulation mechanisms targeting key aspects of ITP disease pathophysiology. buff.ly/2y1gxnZ #hemesky
June 16, 2025 at 7:00 PM
Rilzabrutinib acts through multi-immune modulation mechanisms targeting key aspects of ITP disease pathophysiology. buff.ly/2y1gxnZ #hemesky
Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
www.globenewswire.com/news-release...
www.globenewswire.com/news-release...
Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP Pivotal phase 3 data show rapid...
www.globenewswire.com
December 8, 2024 at 11:32 PM
Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
www.globenewswire.com/news-release...
www.globenewswire.com/news-release...
Für die chronische spontane Urtikaria, die auf H1-Antihistaminika nicht ausreichend anspricht, zeichnet sich mit den Bruton-Tyrosin-Kinase-Inhibitoren (BTKi) eine neue Therapieoption ab: Vielversprechende Ergebnisse gibt es jetzt für den oralen reversiblen BTKi Rilzabrutinib. #Derma #medsky
BTK-Hemmer wirkt bei Versagen von H1-Antihistaminika
Für die chronische spontane Urtikaria, die auf H1-Antihistaminika nicht ausreichend anspricht, zeichnet sich mit den Bruton-Tyrosin-Kinase-Inhibitoren (BTKi) eine neue Therapieoption ab: Vielversprechende Ergebnisse wurden jetzt für den oralen reversiblen BTKi Rilzabrutinib veröffentlicht.
www.springermedizin.de
May 26, 2025 at 6:39 PM
The umbrella allows us to pool the control group so we ghet three interventions for every one placebo patient.
There umbrella trial is called RESULT
• anti-CD40 monoclonal AB
• inhibitor of AntiOX40L and TNF alpha
• Rilzabrutinib, a Bruton’s tyrosine kinase inhibitor to modulate B-cell signaling
There umbrella trial is called RESULT
• anti-CD40 monoclonal AB
• inhibitor of AntiOX40L and TNF alpha
• Rilzabrutinib, a Bruton’s tyrosine kinase inhibitor to modulate B-cell signaling
September 24, 2025 at 6:39 PM
The umbrella allows us to pool the control group so we ghet three interventions for every one placebo patient.
There umbrella trial is called RESULT
• anti-CD40 monoclonal AB
• inhibitor of AntiOX40L and TNF alpha
• Rilzabrutinib, a Bruton’s tyrosine kinase inhibitor to modulate B-cell signaling
There umbrella trial is called RESULT
• anti-CD40 monoclonal AB
• inhibitor of AntiOX40L and TNF alpha
• Rilzabrutinib, a Bruton’s tyrosine kinase inhibitor to modulate B-cell signaling
Rilzabrutinib ITP Brand Manager - Tokyo Job educativ.net/jobs/job/41845...
July 24, 2025 at 6:58 AM
Rilzabrutinib ITP Brand Manager - Tokyo Job educativ.net/jobs/job/41845...
2/2 Il agit par modulation multi-immune, afin de réduire les crises vaso-occlusives de la drépanocytose
www.globenewswire.com/news-release...
www.globenewswire.com/news-release...
Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease
Rilzabrutinib granted orphan drug designation in the US for sickle cell disease Fourth orphan drug designation for rilzabrutinib in rare diseasesUnder...
www.globenewswire.com
June 3, 2025 at 2:42 PM
2/2 Il agit par modulation multi-immune, afin de réduire les crises vaso-occlusives de la drépanocytose
www.globenewswire.com/news-release...
www.globenewswire.com/news-release...
Sanofi's rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan ... - goo.gl/alerts/RqMpYS #GoogleAlerts
Press Release: Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia
goo.gl
February 9, 2026 at 8:52 PM
Sanofi's rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan ... - goo.gl/alerts/RqMpYS #GoogleAlerts
1/2 La FDA accorde la désignation de médicament orphelin au rilzabrutinib, de sanofi, pour le traitement de la drépanocytose.
Le rilzabrutinib est un inhibiteur de la tyrosine kinase de Bruton (BTK), avancé, oral et réversible
Le rilzabrutinib est un inhibiteur de la tyrosine kinase de Bruton (BTK), avancé, oral et réversible
June 3, 2025 at 2:42 PM
1/2 La FDA accorde la désignation de médicament orphelin au rilzabrutinib, de sanofi, pour le traitement de la drépanocytose.
Le rilzabrutinib est un inhibiteur de la tyrosine kinase de Bruton (BTK), avancé, oral et réversible
Le rilzabrutinib est un inhibiteur de la tyrosine kinase de Bruton (BTK), avancé, oral et réversible
ICYMI: The FDA last Friday approved rilzabrutinib under the name Wayrilz for treating immune thrombocytopenia. Read More:
FDA Approves BTK Inhibitor Rilzabrutinib for Immune Thrombocytopenia
The FDA has approved the therapy, marketed as Wayrilz, a new treatment for chronic immune thrombocytopenia.
www.hcplive.com
September 3, 2025 at 12:00 PM
ICYMI: The FDA last Friday approved rilzabrutinib under the name Wayrilz for treating immune thrombocytopenia. Read More:
The U.S. FDA has granted breakthrough therapy designation and Japan’s MHLW has designated orphan drug status to Sanofi’s BTK inhibitor, rilzabrutinib (Wayrilz), as a treatment for wAIHA.
Read here👇
www.thepharmanavigator.com/news/rilzabr...
Read here👇
www.thepharmanavigator.com/news/rilzabr...
Rilzabrutinib Gains Regulatory Nods in the U.S. and Japan — The Pharma Navigator - Navigating The Key News Stories In Pharma
The U.S. FDA has granted breakthrough therapy designation and Japan’s MHLW has designated orphan drug status to Sanofi’s BTK inhibitor, rilzabrutinib (Wayrilz), as a treatment for wAIHA.
www.thepharmanavigator.com
February 19, 2026 at 12:45 PM
The U.S. FDA has granted breakthrough therapy designation and Japan’s MHLW has designated orphan drug status to Sanofi’s BTK inhibitor, rilzabrutinib (Wayrilz), as a treatment for wAIHA.
Read here👇
www.thepharmanavigator.com/news/rilzabr...
Read here👇
www.thepharmanavigator.com/news/rilzabr...
Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Adults with Previously Treated Immune Thrombocytopenia (ITP): A Phase 3, Placebo-Controlled, Parallel-Group, Multicenter Study (LUNA 3) [Dec 8, 2024] Kuter et al. #ASH24 Abst 5 - Plenary ash.confex.com/ash/2024/web... #ITP
Paper: Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Adults with Previously Treated Immune Thrombocytopenia (ITP): A Phase 3, Placebo-Controlled, Parallel-Group,...
ash.confex.com
February 2, 2025 at 8:02 PM
Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Adults with Previously Treated Immune Thrombocytopenia (ITP): A Phase 3, Placebo-Controlled, Parallel-Group, Multicenter Study (LUNA 3) [Dec 8, 2024] Kuter et al. #ASH24 Abst 5 - Plenary ash.confex.com/ash/2024/web... #ITP
From the #Transfusion Evidence Round-Up - Best of the Transfusion Evidence Library 2025:
Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study
by Kuter et al.
www.transfusionevidencelibrary.com/articles/400...
#MedSky
Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study
by Kuter et al.
www.transfusionevidencelibrary.com/articles/400...
#MedSky
December 22, 2025 at 7:29 AM
From the #Transfusion Evidence Round-Up - Best of the Transfusion Evidence Library 2025:
Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study
by Kuter et al.
www.transfusionevidencelibrary.com/articles/400...
#MedSky
Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study
by Kuter et al.
www.transfusionevidencelibrary.com/articles/400...
#MedSky
#Japan has approved #Sanofi’s #Wayrilz (#rilzabrutinib) for persistent or chronic immune thrombocytopenia. The approval is backed by Phase 3 LUNA 3 data
www.ipharmacenter.com/post/japan-a...
#ITP #BTKInhibitor #News #pharma #pharmaceutical #healthcare #globalhealth #healthforall
www.ipharmacenter.com/post/japan-a...
#ITP #BTKInhibitor #News #pharma #pharmaceutical #healthcare #globalhealth #healthforall
Japan Approves Sanofi’s Wayrilz for Chronic Immune Thrombocytopenia Treatment | iPharmaCenter
Sanofi has received approval in Japan for Wayrilz (rilzabrutinib) to treat adults with persistent or chronic immune thrombocytopenia (ITP), particularly in patients who have shown inadequate response ...
www.ipharmacenter.com
June 23, 2026 at 5:32 PM
#Japan has approved #Sanofi’s #Wayrilz (#rilzabrutinib) for persistent or chronic immune thrombocytopenia. The approval is backed by Phase 3 LUNA 3 data
www.ipharmacenter.com/post/japan-a...
#ITP #BTKInhibitor #News #pharma #pharmaceutical #healthcare #globalhealth #healthforall
www.ipharmacenter.com/post/japan-a...
#ITP #BTKInhibitor #News #pharma #pharmaceutical #healthcare #globalhealth #healthforall
#Japan genehmigt #Sanofi #Wayrilz (#Rilzabrutinib) zur Behandlung der persistenten oder chronischen immunen Thrombozytopenie. Die Zulassung basiert auf den Daten der Phase-3-Studie LUNA 3. www.ipharmacenter.com/post/japan-a...
#Nachrichten #Pharma #Gesundheitswesen
#Nachrichten #Pharma #Gesundheitswesen
Japan Approves Sanofi’s Wayrilz for Chronic Immune Thrombocytopenia Treatment | iPharmaCenter
Sanofi has received approval in Japan for Wayrilz (rilzabrutinib) to treat adults with persistent or chronic immune thrombocytopenia (ITP), particularly in patients who have shown inadequate response ...
www.ipharmacenter.com
June 23, 2026 at 5:38 PM
#Japan genehmigt #Sanofi #Wayrilz (#Rilzabrutinib) zur Behandlung der persistenten oder chronischen immunen Thrombozytopenie. Die Zulassung basiert auf den Daten der Phase-3-Studie LUNA 3. www.ipharmacenter.com/post/japan-a...
#Nachrichten #Pharma #Gesundheitswesen
#Nachrichten #Pharma #Gesundheitswesen
Promising advances in #ImmuneThrombocytopenia (ITP) treatment: #SpleenTyrosineKinase and Bruton's tyrosine kinase inhibitors like fostamatinib, sovleplenib, rilzabrutinib, and orelabrutinib improve platelet counts and safety in refractory #ITP #Aminopyridines. onlinelibrary.wiley.com/doi/10.1155/...
Efficacy and Safety of Syk and BTK Inhibitors in Immune Thrombocytopenia: A Comprehensive Review of Emerging Evidence
Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by a reduced platelet count, resulting in bleeding risks and compromised quality of life. Advances in understanding ITP pathogene....
onlinelibrary.wiley.com
August 13, 2025 at 6:52 AM
Promising advances in #ImmuneThrombocytopenia (ITP) treatment: #SpleenTyrosineKinase and Bruton's tyrosine kinase inhibitors like fostamatinib, sovleplenib, rilzabrutinib, and orelabrutinib improve platelet counts and safety in refractory #ITP #Aminopyridines. onlinelibrary.wiley.com/doi/10.1155/...
日本、持続性または慢性の免疫性血小板減少症（ITP）治療薬としてサノフィの「Wayrilz（リルザブルチニブ）」を承認。フェーズ3のLUNA 3試験データに基づく承認。 www.ipharmacenter.com/post/japan-a...
#日本 #サノフィ #Wayrilz #リルザブルチニブ #ITP #BTK阻害薬 #ニュース #製薬 #ヘルスケア #グローバルヘルス
#日本 #サノフィ #Wayrilz #リルザブルチニブ #ITP #BTK阻害薬 #ニュース #製薬 #ヘルスケア #グローバルヘルス
Japan Approves Sanofi’s Wayrilz for Chronic Immune Thrombocytopenia Treatment | iPharmaCenter
Sanofi has received approval in Japan for Wayrilz (rilzabrutinib) to treat adults with persistent or chronic immune thrombocytopenia (ITP), particularly in patients who have shown inadequate response ...
www.ipharmacenter.com
June 23, 2026 at 5:35 PM
Abstract 5️⃣ Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Adults with Previously Treated Immune Thrombocytopenia (ITP): A Phase 3, Placebo-Controlled, Parallel-Group, Multicenter Study (LUNA 3). Kuter DJ, et al. #ITP #BTKi bit.ly/3V13XXz
November 19, 2024 at 4:46 PM
Abstract 5️⃣ Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Adults with Previously Treated Immune Thrombocytopenia (ITP): A Phase 3, Placebo-Controlled, Parallel-Group, Multicenter Study (LUNA 3). Kuter DJ, et al. #ITP #BTKi bit.ly/3V13XXz
On August 29, 2025, the FDA approved rilzabrutinib, an oral BTK inhibitor, for adults with persistent or chronic immune thrombocytopenia.🩸
Read our article to learn more & to hear about the potential role of this agent from Hanny Al-Samkari of @mgbresearch.bsky.social:
🗞️ 👉 ow.ly/wEU250WP5GQ
Read our article to learn more & to hear about the potential role of this agent from Hanny Al-Samkari of @mgbresearch.bsky.social:
🗞️ 👉 ow.ly/wEU250WP5GQ
September 1, 2025 at 1:54 PM
On August 29, 2025, the FDA approved rilzabrutinib, an oral BTK inhibitor, for adults with persistent or chronic immune thrombocytopenia.🩸
Read our article to learn more & to hear about the potential role of this agent from Hanny Al-Samkari of @mgbresearch.bsky.social:
🗞️ 👉 ow.ly/wEU250WP5GQ
Read our article to learn more & to hear about the potential role of this agent from Hanny Al-Samkari of @mgbresearch.bsky.social:
🗞️ 👉 ow.ly/wEU250WP5GQ
En direct de l'#ASH24 avec nos internes reporters MaRIH
Rilzabrutinib (iBTK) vs placebo, essai de phase 3
PTI chronique ou persistant en échec de lignes antérieures
Critère de jugement principal : réponse durable à 6 mois sans traitement de sauvetage (23% vs 0%, p<0.0001)
Rilzabrutinib (iBTK) vs placebo, essai de phase 3
PTI chronique ou persistant en échec de lignes antérieures
Critère de jugement principal : réponse durable à 6 mois sans traitement de sauvetage (23% vs 0%, p<0.0001)
December 9, 2024 at 7:58 PM
En direct de l'#ASH24 avec nos internes reporters MaRIH
Rilzabrutinib (iBTK) vs placebo, essai de phase 3
PTI chronique ou persistant en échec de lignes antérieures
Critère de jugement principal : réponse durable à 6 mois sans traitement de sauvetage (23% vs 0%, p<0.0001)
Rilzabrutinib (iBTK) vs placebo, essai de phase 3
PTI chronique ou persistant en échec de lignes antérieures
Critère de jugement principal : réponse durable à 6 mois sans traitement de sauvetage (23% vs 0%, p<0.0001)
サノフィのWayrilz（リルザブルチニブ）が、日本で持続性または慢性の免疫性血小板減少症（ITP）の治療薬として承認されました。
www.ipharmacenter.com/post/japan-a...
#ITP #サノフィ #Wayrilz #日本承認 #ニュース #製薬 #医薬品 #医療
www.ipharmacenter.com/post/japan-a...
#ITP #サノフィ #Wayrilz #日本承認 #ニュース #製薬 #医薬品 #医療
Japan Approves Sanofi’s Wayrilz for Chronic Immune Thrombocytopenia Treatment | iPharmaCenter
Sanofi has received approval in Japan for Wayrilz (rilzabrutinib) to treat adults with persistent or chronic immune thrombocytopenia (ITP), particularly in patients who have shown inadequate response ...
www.ipharmacenter.com
June 26, 2026 at 4:55 AM
What if your immune system attacked your own blood?
That's daily life for ITP patients. On Sept 3, China's NMPA approved a new option: Sanofi's Wayrilz® (rilzabrutinib) — an oral BTK inhibitor for patients who've run out of choices.
Follow for global drug updates 👇
#ITP #Biotech
That's daily life for ITP patients. On Sept 3, China's NMPA approved a new option: Sanofi's Wayrilz® (rilzabrutinib) — an oral BTK inhibitor for patients who've run out of choices.
Follow for global drug updates 👇
#ITP #Biotech
September 4, 2026 at 7:24 AM